



Date: November 6, 2025

BSE Limited
Corporate Relations Department
Phiroze Jeejeebhoy Towers
Dalal Street
Fort, Mumbai 400 001
Maharashtra, India

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, Plot No. C/1, G Block
Bandra Kurla Complex
Bandra (East), Mumbai 400 051
Maharashtra, India

Scrip Code: 532321

Symbol: ZYDUSLIFE

Dear Madam / Sir

Sub: Outcome of the meeting of the Board of Directors of Zydus Lifesciences Limited ("the Company") pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")

Pursuant to regulation 30 of the Listing Regulations, we hereby inform that the Board of Directors at its meeting held today has, *inter-alia*, considered and approved raising of funds by way of issuance of eligible securities of the Company for an aggregate amount not exceeding Rs. 5,000 Crores (Rupees Five Thousand Crores only) in one or more tranches by way of qualified institutions placement(s), rights issue, preferential allotment or a private placement(s) and / or any combination thereof or any other method as may be permitted under applicable laws, subject to the approval of the members of the Company and such regulatory / statutory approvals as may be required, to the eligible investors. The Board of Directors have authorized a committee of the Board to take all the necessary decisions in this regard.

This outcome of the Board meeting will be available on the Company's website, i.e. www.zyduslife.com.

The Board also approved the postal ballot notice to be issued to the members seeking approval for the above matter, as appropriate. The postal ballot notice with further details will be sent separately.

The Board meeting of the Company commenced at 11:00 a.m. and concluded at 1:00 p.m.

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





The detailed disclosure as required under regulation 30 of the Listing Regulations read with the SEBI Circulars is enclosed as **Annexure-“A”**.

You are requested to take the same on record.

Thanking you,

For, **Zydus Lifesciences Limited**

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Annexure-“A”

Disclosure as per regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circulars dated November 11, 2024, and December 31, 2024

Sr. No.	Details of Events that need to be provided	Information of such event(s)
1.	Type of securities proposed to be issued (viz., equity shares, convertibles, etc.)	Such instrument or security, including equity shares, non-convertible debentures, along with warrants, or convertible securities other than warrants or any other equity based securities or in combination of any of the Securities, as permitted under applicable law (all of which are hereinafter referred to as “the Securities ”) as may be decided by the Board or any Committee thereof (“the Board ”), in one or more tranches and / or one or more issuances.
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR / GDR), qualified institutions placement, preferential allotment etc.)	Qualified Institutional Placement (“ QIP ”) in accordance with the provisions of Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, rights issue, preferential allotment, private placement(s) and / or any combination thereof or any other method as may be permitted under applicable laws.
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Issuance of Securities up to an aggregate amount of ₹ 5,000 crores, in one or more tranches and / or by way of one or more issuances.

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Sr. No.	Details of Events that need to be provided	Information of such event(s)
4.	in case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s): i. names of the investors; ii. post allotment of securities-outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors; iii. in case of convertibles-intimation on conversion of securities or on lapse of the tenure of the instrument;	To be determined by the Board as per the requirements prescribed under applicable law, at the appropriate time.
5.	in case of bonus issue the listed entity shall disclose the following additional details to the stock exchange(s): i. whether bonus is out of free reserves created out of profits or share premium account; ii. bonus ratio; iii. details of share capital -pre and post bonus issue; iv. free reserves and / or share premium required for implementing the bonus issue; v. free reserves and/ or share premium available for capitalization and the date as on which such balance is available;	Not applicable

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



	vi. whether the aforesaid figures are audited; vii. estimated date by which such bonus shares would be credited/dispatched;	
6.	in case of issuance of depository receipts (ADR / GDR) or FCCB the listed entity shall disclose following additional details to the stock exchange(s): i. name of the stock exchange(s) where ADR / GDR / FCCBs are listed (opening-closing status) / proposed to be listed; ii. proposed no. of equity shares underlying the ADR / GDR or on conversion of FCCBs; iii. proposed date of allotment, tenure, date of maturity and coupon offered, if any of FCCBs; iv. issue price of ADR / GDR / FCCBs (in terms of USD and in INR after considering conversion rate); v. change in terms of FCCBs, if any; vi. details of defaults, if any, by the listed entity in payment of coupon on FCCBs & subsequent updates in relation to the default, including the details of the corrective measures undertaken (if any);	Not applicable

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Sr. No.	Details of Events that need to be provided	Information of such event(s)
7.	in case of issuance of debt securities or other non-convertible securities the listed entity shall disclose following additional details to the stock exchange(s): - size of the issue; - whether proposed to be listed? If yes, name of the stock exchange(s); - tenure of the instrument -date of allotment and date of maturity; - coupon/interest offered, schedule of payment of coupon/interest and principal; - charge/security, if any, created over the assets; - special right / interest / privileges attached to the instrument and changes thereof; - delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal; - details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any; - details of redemption of preference shares indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures;	To be determined by the Board as per the requirements prescribed under applicable law, at the appropriate time.

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Sr. No.	Details of Events that need to be provided	Information of such event(s)
8.	Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not applicable

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

